Biotechnology Children\\\'s Health Child Psychology Child Development
Friday, June 3, 2011
Seaside Therapeutics Initiates Pivotal Phase 3 Study Of STX209 In Fragile X Syndrome
Seaside Therapeutics, Inc. announced today the initiation of a randomized, double-blind, placebo-controlled Phase 3 study to evaluate the effects of STX209 (arbaclofen) on social impairment in adolescents and adults (ages 12 to 25) with fragile X syndrome. A second study in children (ages 5 to 11) is expected to begin in early summer. STX209 is an oral selective gamma-amino butyric acid type B (GABA-B) receptor agonist...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment